智通财经APP获悉，和铂医药-B(02142)再涨近7%，股价自去年12月17日至今累计涨幅已超370%，截至发稿，涨6.3%，报5.4港元，成交额3490.56万港元。
消息面上，和铂医药近期发盈喜，预期截至2024年12月31日止年度的溢利将介于人民币730万元至2200万元。期内，公司的现金溢利达到人民币2.20亿元的历史新高。此外，公司于2月14日斥资171.48万港元回购股份43.6万股。
智通财经APP在《和铂医药-B（02142）的BD突围：2.2亿现金利润能否改写Biotech生存逻辑？》中指出，和铂医药这一波行情的背后是多重利好的共振，包括回购计划提振信心、授权合作增加现金流收入、核心管线进展及业绩大增。和铂医药凭借其独特的Harbour Mice平台技术，成功吸引了辉瑞、阿斯利康、默沙东等全球制药巨头的合作，自2022年以来累计达成了超过40亿美元的里程碑交易。总的来说，和铂医药在技术平台和商业模式上的创新为其赢得了资本市场的认可，但如何在激烈的市场竞争中保持持续增长，仍需公司在商业化能力和创新研发上不断突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.